
Candel Therapeutics, Inc. (NASDAQ:CADL – Free Report) – Investment analysts at HC Wainwright issued their Q4 2027 earnings per share (EPS) estimates for Candel Therapeutics in a report released on Friday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.22) per share.
Other research analysts also recently issued research reports about the company. Jefferies Financial Group initiated coverage on Candel Therapeutics in a research note on Thursday, October 22nd. They issued a “buy” rating and a $25.00 target price for the company. Zacks Research lowered Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Wednesday, October 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Candel Therapeutics in a research report on Thursday, October 15th. Canaccord Genuity Group decreased their price target on Candel Therapeutics from $25.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, November 13th. Finally, UBS Group reissued a “buy” rating on shares of Candel Therapeutics in a report on Monday, August 17th. Nine investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $18.29.
Get Our Latest Analysis on Candel Therapeutics
Candel Therapeutics Stock Performance
NASDAQ:CADL opened at $5.40 on Monday. The company has a debt-to-equity ratio of 0.37, a quick ratio of 7.57 and a current ratio of 7.57. Candel Therapeutics has a 52-week low of $4.35 and a 52-week high of $14.00. The firm has a market cap of $423.63 million, a price-to-earnings ratio of -3.65 and a beta of -0.27. The business’s fifty day moving average is $9.47 and its 200 day moving average is $8.39.
Candel Therapeutics (NASDAQ:CADL – Get Free Report) last announced its quarterly earnings results on Friday, November 13th. The company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.06.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in CADL. Portolan Capital Management LLC increased its holdings in shares of Candel Therapeutics by 1.4% in the third quarter. Portolan Capital Management LLC now owns 3,538,561 shares of the company’s stock worth $36,943,000 after purchasing an additional 48,163 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Candel Therapeutics by 4.1% in the third quarter. Goldman Sachs Group Inc. now owns 317,601 shares of the company’s stock worth $3,316,000 after buying an additional 12,385 shares in the last quarter. Cetera Investment Advisers purchased a new stake in shares of Candel Therapeutics in the third quarter worth $124,000. Entropy Technologies LP bought a new stake in Candel Therapeutics during the third quarter valued at $266,000. Finally, Jump Financial LLC boosted its stake in Candel Therapeutics by 22.2% during the third quarter. Jump Financial LLC now owns 130,579 shares of the company’s stock valued at $1,363,000 after buying an additional 23,739 shares during the period. 13.93% of the stock is currently owned by hedge funds and other institutional investors.
Trending Headlines about Candel Therapeutics
These are some of the CADL headlines that stood out recently:
- Neutral Sentiment: HC Wainwright maintained its Buy rating and $18 price target, while raising its FY2026 loss estimate. The target is a supportive signal, but the firm’s longer-range forecasts were cut substantially. MarketBeat analyst estimates
- Negative Sentiment: HC Wainwright lowered projected earnings for FY2027 through FY2030, including moving its FY2028 estimate from a profit to a loss. Brookline’s estimates also point to ongoing quarterly losses through 2027, reinforcing concerns about the path to profitability. MarketBeat analyst estimates
- Negative Sentiment: Law firms announced investigations and investor notices following Candel’s delay of its aglatimagene biologics license application (BLA) for prostate cancer to mid-2027. The notices allege potential securities-law issues; they are not findings of wrongdoing. The filing delay had already triggered a sharp selloff, and the legal scrutiny could add uncertainty. SBS Law investigation notice Levi and Korsinsky investigation notice
About Candel Therapeutics
Candel Therapeutics is a clinical-stage biotechnology company developing viral immunotherapies designed to stimulate the immune system to fight cancer. Its approach uses engineered viruses to trigger immune responses against tumors. The company’s clinical-stage programs include CAN-2409, an adenovirus-based therapy being studied in several solid tumors, and CAN-3110, an oncolytic herpes simplex virus therapy being investigated for recurrent glioblastoma. Based in Needham, Massachusetts, Candel conducts clinical development of its therapies for cancer indications.
Featured Articles
- Five stocks we like better than Candel Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Candel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Candel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
